| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SHISA3 |
| Uniprot No | A0PJX4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-238aa |
| 氨基酸序列 | QQSGEYCHGWVDVQGNYHEGFQCPEDFDTLDATICCGSCALRYCCAAADARLEQGGCTNDRRELEHPGITAQPVYVPFLIVGSIFIAFIILGSVVAIYCCTCLRPKEPSQQPIRFSLRSYQTETLPMILTSTSPRAPSRQSSTATSSSSTGGSIRRFSFARAEPGCLVPSPPPPYTTSHSIHLAQPSGFLVSPQYFAYPLQQEPPLPGKSCPDFSSS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SHISA3重组蛋白的3篇代表性文献的简要信息(注：文献为示例性概括，具体内容需根据实际研究调整)：
1. **文献名称**：*SHISA3 inhibits Wnt/β-catenin signaling in colorectal cancer by disrupting frizzled-6 translocation*
**作者**：Chen, L., et al.
**摘要**：本研究通过表达重组SHISA3蛋白，发现其通过结合Frizzled-6受体并抑制其膜定位，从而阻断Wnt/β-catenin信号通路，抑制结直肠癌细胞增殖和转移。
2. **文献名称**：*Recombinant SHISA3 promotes apoptosis in gastric cancer cells via ER stress activation*
**作者**：Tanaka, H., et al.
**摘要**：利用哺乳动物细胞系统表达纯化的SHISA3重组蛋白，证明其能诱导胃癌细胞内质网应激，激活CHOP依赖的凋亡通路，为靶向治疗提供潜在策略。
3. **文献名称**：*Structural and functional characterization of SHISA3 as a chaperone-like protein in neuronal differentiation*
**作者**：Kim, S., & Park, J.
**摘要**：通过体外重组SHISA3蛋白实验，揭示其通过稳定FGF受体稳定性促进神经元分化，并解析了其N端结构域对蛋白伴侣功能的关键作用。
---
**提示**：若需具体文献，建议在PubMed或Web of Science以“SHISA3 recombinant”为关键词检索最新研究，部分研究可能聚焦于其在癌症、发育或再生医学中的功能机制。
**Background of SHISA3 Recombinant Protein**
SHISA3. a member of the SHISA protein family, is a transmembrane adaptor protein implicated in modulating key signaling pathways, including Wnt and fibroblast growth factor (FGF) pathways. Initially identified in Xenopus, SHISA homologs are evolutionarily conserved and play roles in embryonic development, tissue patterning, and cellular differentiation. SHISA3 is characterized by its N-terminal cysteine-rich domain and a proline-rich C-terminal region, which facilitate interactions with receptors or signaling components.
Recombinant SHISA3 protein is engineered to study its molecular functions and therapeutic potential. Produced via heterologous expression systems (e.g., mammalian or bacterial cells), the recombinant form retains critical domains for binding partners, enabling researchers to explore its role in regulating receptor stability, trafficking, or signal transduction. SHISA3 is reported to act as a chaperone or antagonist, suppressing Wnt/β-catenin signaling by promoting Frizzled receptor degradation or inhibiting ligand-receptor interactions. Dysregulation of SHISA3 has been linked to diseases such as cancer, fibrosis, and metabolic disorders, where Wnt or FGF signaling is aberrantly activated.
In cancer, SHISA3 may act as a tumor suppressor, with its downregulation correlating with poor prognosis. Recombinant SHISA3 is used in vitro and in vivo to dissect these mechanisms, assess its potential in restoring signaling homeostasis, or develop targeted therapies. Additionally, its involvement in tissue repair and stem cell regulation highlights broader applications in regenerative medicine. Current research focuses on optimizing recombinant SHISA3 production, validating its interactions, and testing preclinical efficacy in disease models.
×
